12th January 2024
The International Progressive MS Alliance has released a Request for Applications (RFA) to support innovative Experimental Medicine Trials that advance our knowledge of disease pathophysiology by defining the underlying mechanisms of an intervention, mechanisms of progressive MS pathogenesis, and/or harmonizing outcome measures that correlate with clinical efficacy for any given intervention.
The RFA offers two funding pathways: an Experimental Medicine Trial Award for up to €1.5 million or a Development Award for up to €100,000 that will result in a subsequent opportunity to apply for a full Experimental Medicine Trial Award. Development Awards are for planning, developmental efforts, and/or validation opportunities that support future trials. The inclusion of people with MS in the development of Alliance initiatives is valuable and essential, and all proposed applications must be developed with, and informed by, perspectives of people affected by progressive MS, including trial design and execution.